Abstract: The antibacterial compound of formula I wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; A1, A2, A3, R1 and R4 represent various substituents, G represents aryl or heteroaryl, which is unsubstituted or substituted which compounds show good activity against pathogenic bacteria.
Type:
Grant
Filed:
March 17, 2014
Date of Patent:
January 6, 2015
Assignee:
Basilea Pharmaceutica AG
Inventors:
Berangere Gaucher, Franck Hubert Danel, Patrick Roussel
Abstract: A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril.
Type:
Application
Filed:
September 15, 2014
Publication date:
January 1, 2015
Applicant:
Basilea Pharmaceutica AG
Inventors:
Marco Alpegiani, JR., Walter Cabri, Markus Heubes, Davide Longoni, Michael Schleimer
Abstract: New monobactam antibiotics compounds which contain an 3-amino-azetidin-2-one ring and are active against gram-negative bacteria, wherein the compounds include the compound 2-(2-amino-thiazol-4-yl)-2-[(Z)-(1H,4H-1,5-dihydroxy-4-oxo-pyridin-2-yl)methoxyimino]-N-[3(S)-1-oxysulfonyl-2,2-dimethyl-4-oxo-azetidin-3-yl]acetamide.
Type:
Grant
Filed:
December 7, 2006
Date of Patent:
December 2, 2014
Assignee:
Basilea Pharmaceutica AG
Inventors:
Eric Desarbre, Bérangére Gaucher, Malcolm G. P. Page, Patrick Roussel
Abstract: C1-C6Alkyloxy- or benzyloxy-carbonyl esters of -{3-[(E)-(1-phenyl or naphthyl C1-C4alkyl)-imino]-propyl}-amino)-acetic acid, which are intermediates for producing known bridged monobactam compounds useful in the treatment of bacterial infections.
Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.
Type:
Grant
Filed:
August 13, 2010
Date of Patent:
October 21, 2014
Assignee:
Basilea Pharmaceutica AG
Inventors:
Johannes Laurenz Kellenberger, Jürg Dreier
Abstract: A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril.
Type:
Grant
Filed:
April 14, 2009
Date of Patent:
October 21, 2014
Assignee:
Basilea Pharmaceutica AG
Inventors:
Marco Alpegiani, Walter Cabri, Markus Heubes, Davide Longoni, Michael Schleimer
Abstract: Use of a monobactam antibiotic of formula (I) wherein the oxyimino group i.e. >C?N—O— has Z-orientation, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a bacterial infection in combination with a carbapenem antibiotic or a pharmaceutically acceptable salt thereof.
Abstract: A compound of formula II in which Z is C or N and the Z ring is optionally further substituted; R1 is H, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; and R2 is a group selected from (b), (c), and (d):
Abstract: The antibacterial compound of formula I wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; A1, A2, A3, R1 and R4 represent various substituents, G represents aryl or heteroaryl, which is unsubstituted or substituted which compounds show good activity against pathogenic bacteria.
Type:
Application
Filed:
March 17, 2014
Publication date:
August 7, 2014
Applicant:
Basilea Pharmaceutica AG
Inventors:
Berangere Gaucher, Franck Hubert Danel, Patrick Roussel
Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.
Type:
Application
Filed:
January 24, 2014
Publication date:
May 22, 2014
Applicant:
BASILEA PHARMACEUTICA AG
Inventors:
Johannes Laurenz Kellenberger, Jürg Dreier
Abstract: The antibacterial compound of formula I wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; A1, A2, A3, R1 and R4 represent various substituents, G represents aryl or heteroaryl, which is unsubstituted or substituted which compounds show good activity against pathogenic bacteria.
Type:
Grant
Filed:
January 21, 2010
Date of Patent:
May 6, 2014
Assignee:
Basilea Pharmaceutica AG
Inventors:
Berangere Gaucher, Franck Hubert Danel, Patrick Roussel
Abstract: Use of glu-tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).
Abstract: Use of stathmin as a biomarker for predicting the response, such as resistance, to a compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).
Abstract: C1-C6Alkyloxy- or benzyloxy-carbonyl esters of -{3-[(E)-(1-phenyl or naphthyl C1-C4alkyl)-imino]-propyl}-amino)-acetic acid, which are intermediates for producing known bridged monobactam compounds useful in the treatment of bacterial infections.
Abstract: A pharmaceutical composition for oral administration which is self-emulsifying on contact with an aqueous phase, in particular gastrointestinal fluids, and which comprises: (a) an antifungally active compound of formula (I) wherein R1, R2 and R3 are independently of one another hydrogen, F or Cl; or a pharmaceutically acceptable acid addition salt thereof, and (b) a carrier comprising a solubilizer component for the antifungally effective component (a).
Type:
Grant
Filed:
August 20, 2008
Date of Patent:
September 17, 2013
Assignee:
Basilea Pharmaceutica AG
Inventors:
Christian Bucher, Günter Ditzinger, Estelle Dubois, Delphine Marchaud
Abstract: Use of a monobactam antibiotic of formula (I) wherein the oxyimino group i.e. >C?N—O— has Z-orientation, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a bacterial infection in combination with a carbapenem antibiotic or a pharmaceutically acceptable salt thereof.
Abstract: The invention relates to novel substituted 2-(phenyl-, pyridyl- or pyrimidyl-carbonyl)-furanes and -thiophenes and related phenoxy/phenylthio-acetophenones and corresponding heterocyclic compounds, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of neoplastic diseases and autoimmune diseases, and a method for the treatment of such a diseases.
Type:
Grant
Filed:
May 12, 2006
Date of Patent:
July 16, 2013
Assignee:
Basilea Pharmaceutica AG
Inventors:
Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Goutam Saha, Subir Kumar Sadhukhan, Rohit Saxena, Sudhir Srivastava
Abstract: Macrolides of Formula (I) or (I-A): and wherein the residues R1, R2, R3, R4, R12, R13 and R14 have certain meanings defined in this application are useful for treating or preventing inflammatory or allergic diseases or, cancer in animals and humans.
Type:
Grant
Filed:
February 9, 2009
Date of Patent:
May 21, 2013
Assignee:
Basilea Pharmaceutica AG
Inventors:
Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
Abstract: The invention relates to antibiotic macrolides of formula (I), which have improved anti-inflammatory activity mediated through inhibition of phosphodiesterase 4 (PDE4) useful for the treatment and/or prevention of inflammatory, allergic and proliferative diseases.
Type:
Grant
Filed:
February 9, 2009
Date of Patent:
April 2, 2013
Assignee:
Basilea Pharmaceutica AG
Inventors:
Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.
Type:
Application
Filed:
August 13, 2010
Publication date:
November 1, 2012
Applicant:
BASILEA PHARMACEUTICA AG
Inventors:
Johannes Laurenz Kellenberger, Jürg Dreier